Cite
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
MLA
Thielmann, Carl M., et al. “NF1-Mutated Melanomas Reveal Distinct Clinical Characteristics Depending on Tumour Origin and Respond Favourably to Immune Checkpoint Inhibitors.” European Journal of Cancer (Oxford, England : 1990), vol. 159, Dec. 2021, pp. 113–24. EBSCOhost, https://doi.org/10.1016/j.ejca.2021.09.035.
APA
Thielmann, C. M., Chorti, E., Matull, J., Murali, R., Zaremba, A., Lodde, G., Jansen, P., Richter, L., Kretz, J., Möller, I., Sucker, A., Herbst, R., Terheyden, P., Utikal, J., Pföhler, C., Ulrich, J., Kreuter, A., Mohr, P., Gutzmer, R., … Griewank, K. G. (2021). NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. European Journal of Cancer (Oxford, England : 1990), 159, 113–124. https://doi.org/10.1016/j.ejca.2021.09.035
Chicago
Thielmann, Carl M, Eleftheria Chorti, Johanna Matull, Rajmohan Murali, Anne Zaremba, Georg Lodde, Philipp Jansen, et al. 2021. “NF1-Mutated Melanomas Reveal Distinct Clinical Characteristics Depending on Tumour Origin and Respond Favourably to Immune Checkpoint Inhibitors.” European Journal of Cancer (Oxford, England : 1990) 159 (December): 113–24. doi:10.1016/j.ejca.2021.09.035.